Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Disney announced the merchandise collections for this year’s EPCOT International Food & Wine Festival and shared a preview of ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Regeneron Pharmaceuticals has a price-to-sales (P/S) ratio of 4.6 versus a figure of 3.0 for the S&P 500 Moreover, the company’s price-to-free cash flow (P/FCF) ratio stands at 16.4 in contrast ...

Regeneron shareholders will be glad to learn that the drugmaker's $256 million bid does not include Lemonaid Health, the telehealth operation that 23andMe acquired for $400 million in 2021.

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron announced the purchase Monday. In March, 23andMe initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court to be sold. 23andMe offers DNA testing with an ancestry breakdown ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.

Regeneron was one of seven bidders for 23andMe, according to securities filings. Sold for $256 million, 23andMe has fallen far from its heyday.